Dajin Heavy Industry (01081) announced its third-quarter results, with net profit attributable to shareholders of RMB110 million, down 19.97% year-on-year.

Dajin Heavy Industry (01081) released its 2026 third-quarter report. The group achieved operating revenue of RMB1.111 billion, down 5.05% year-on-year; net profit attributable to shareholders of the listed company was RMB110 million, down 19.97% year-on-year; basic earnings per share were RMB0.15.

7 m ago

Robotechnik Intelligent Technology (03757): The Company's overseas listed foreign shares (H shares) have been included in the list of eligible securities under the Stock Connect program.

Robotechnik Intelligent Technology (03757) announced that, in accordance with the relevant provisions of the Implementation Measures for the Shanghai-Hong Kong Stock Connect Business of the Shanghai Stock Exchange and the Implementation Measures for the Shenzhen-Hong Kong Stock Connect Business of the Shenzhen Stock Exchange, the shares issued by Robotechnik Intelligent Technology Co., Ltd. (hereinafter referred to as the "Company") and listed on The Stock Exchange of Hong Kong Limited (hereinafter referred to as "H shares") have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect (hereinafter collectively referred to as "Stock Connect") effective October 26, 2026.

22 m ago

Nexchip Semiconductor Corporation (02249) reported net profit attributable to shareholders of approximately RMB475 million for the first three quarters, down 13.7% year-on-year.

Nexchip Semiconductor Corporation (02249) announced that for the first three quarters of 2026, the company achieved operating revenue of RMB9.31 billion, up 14.52% year-on-year; net profit attributable to shareholders of the listed company was approximately RMB475 million, down 13.7% year-on-year; basic earnings per share were RMB0.24.

24 m ago

CHINA XLX FERT (01866) reported net profit attributable to shareholders of approximately RMB1.138 billion for the first three quarters, up 42% year on year.

China XLX Fertiliser (01866) announced that for the first three quarters of 2026, it achieved operating revenue of RMB23.047 billion (the same unit below), up 28% year on year; net profit of RMB1.522 billion, up 51% year on year; net profit attributable to shareholders of RMB1.138 billion, up 42% year on year; and basic earnings per share of 90.7 cents.

25 m ago

CHINA CHENGTONG (00217) subsidiary enters into a sale and leaseback agreement with Yangquan Huaxin Liquefied Natural Gas

CHINA CHENGTONG (00217) announced that on October 26, 2026, Chengtong Financial Leasing (an indirectly wholly-owned subsidiary of the Company) entered into a sale and leaseback agreement with the lessee (Yangquan Huaxin Liquefied Natural Gas Co., Ltd.), pursuant to which Chengtong Financial Leasing will purchase the leased assets from the lessee and lease the leased assets back to the lessee for a lease term of 3 years, subject to early termination in accordance with the terms and conditions of the sale and leaseback agreement. The leased assets refer to LNG filling, purification, compression, cold box and storage equipment, etc.

29 m ago

ALPHAMAB-B (09966) presented the latest research progress on JSKN003 at the 2026 ESMO Congress.

Alphamab-B (09966) announced that the latest research progress on JSKN003 was presented during the poster display session at the 2026 ESMO Congress. The JSKN003 combination therapy demonstrated outstanding antitumor activity in the first-line treatment of HER2+ GC/GEJ, with the Cohort B regimen standing out in particular: achieving a 100% ORR, with all patients achieving PR, while also showing a more favorable safety profile. This is the first clinical evidence of an ADC combined with its parental antibody achieving enhanced efficacy. These data support continued patient enrollment and longer-term follow-up in this study.

32 m ago

LINKLOGIS-W (09959) Reports Significant Revenue and Profit Growth in First Three Quarters, Continues to Advance AI Strategic Transformation and Global Expansion

LINKLOGIS-W (09959) announced that in the third quarter of 2026, the total number of the Company's core enterprise partners reached 4,029, an increase of 28.1% compared with the end of 2025; the total number of financial institution partners reached 476, an increase of 11.2% compared with the end of 2025. The customer retention rate for supply chain finance technology solutions was 99%.

33 m ago

DYNAGREEN ENV (01330) rose more than 5% on the first day after its results, is the logic of value and growth resonance being validated?

Dynagreen Environmental Protection Group's gain of over 300% over the past nearly three years may precisely reflect the market's continued pricing of its "resonance of value and growth."

33 m ago

Preview of US Stock Market | All three major stock index futures rise together; oil prices edge lower; Brazilian concept stocks plunge in premarket trading; AI trade faces a "critical judgment week."

October 26 (Monday), in pre-market trading, all three major U.S. stock index futures rose together.

33 m ago

CSPC PHARMA (01093): Phase III clinical study results of Anitumab combined with Docetaxel for Injection (Albumin-Bound) (HB1801) for first-line treatment of HER2-positive advanced breast cancer presented as a Proffered Oral Presentation at the 2026 ESMO Annual Meeting

CSPC PHARMA (01093) announced that the interim analysis results of the Phase III clinical study (Study No.: HEALER) of Anitumab Injection (trade name: Ennito) co-developed by the Group and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., in combination with Docetaxel for Injection (Albumin-Bound) (HB1801) for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, were selected as a Late-breaking Abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on October 24, 2026, and were presented as a Proffered Oral Presentation.

34 m ago

CSPC PHARMA (01093): Updated overall survival (OS) results from the Phase III clinical study of Anntibody for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma were presented as a rapid oral presentation at the 2026 ESMO Annual Meeting

CSPC PHARMA (01093) announced that the updated overall survival (OS) analysis results from the Phase III clinical study (Study No.: KC-WISE) of Anntibody Injection (trade name: Ennituo), jointly developed by the Group and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., in combination with chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJA) in patients who had previously failed trastuzumab treatment, were selected as a Late-breaking Abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on October 23, 2026, and were presented as a rapid oral presentation.

40 m ago

DUALITYBIO-B (09606): The global Phase 3 clinical trial of DYNASTY-Breast02 (NCT06018337) has reached its primary study endpoint.

DUALITYBIO-B (09606) announced that the global Phase 3 clinical trial DYNASTY-Breast02 (NCT06018337) has reached its primary study endpoint. The results showed that in patients with HR+/HER2-low metastatic breast cancer who had experienced disease progression after prior endocrine therapy and had not yet received chemotherapy, pacibart trastuzumab (DB-1303/BNT323) (an investigational HER2-targeting antibody-drug conjugate (ADC)) achieved a statistically significant modest improvement in progression-free survival (PFS) compared with the investigator's choice chemotherapy control group. As of this interim analysis, data for the secondary endpoint overall survival (OS) were not yet mature.

51 m ago

Verizon (VZ.US) Q3 results mixed; reaches over US$2 billion AI infrastructure agreement with Amazon.com, Inc. AWS

Verizon (VZ.US) announced its financial results for the third quarter of 2026.

53 m ago

MeiG Smart Technology (03268) achieved a net profit attributable to shareholders of approximately RMB187 million in the first three quarters, a year-on-year increase of 65.19%.

MeiG Smart Technology (03268) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB3.526 billion, a year-on-year increase of 24.99%; net profit attributable to shareholders of the listed company of approximately RMB187 million, a year-on-year increase of 65.19%; and basic earnings per share of RMB0.65.

56 m ago

The Hong Kong Mortgage Corporation Limited's unaudited consolidated profit after tax for the first half of the year was HK$3 billion, a significant year-on-year increase.

On October 26, The Hong Kong Mortgage Corporation Limited (HKMC) announced its 2026 interim results.

1 h ago

Nexchip Semiconductor Corporation (02249) reported third-quarter profit attributable to shareholders of RMB229 million, up 5.23% year on year.

Nexchip Semiconductor Corporation (02249) announced that the Group's revenue for the third quarter of 2026 was RMB3.252 billion, up 9.88% quarter on quarter and up 19.57% year on year; gross profit margin was 25.46%, up 3.18 percentage points quarter on quarter and up 3.55 percentage points year on year. Profit attributable to owners of the Company was RMB229 million, up 17.83% quarter on quarter and up 5.23% year on year; basic earnings per share were RMB0.11.

1 h ago

Germany's October IFO Expectations Index rises for a sixth consecutive month to 91.6: Economic recovery continues, yet structural gaps remain unbridged

Germany's Ifo economic research institute's October business expectations index unexpectedly rose for a sixth consecutive month, climbing to 91.6 from 90.4 in September, whereas economists surveyed by the market had widely expected a slight decline to 90.

1 h ago

Fed Expected to Hold Rates Steady This Week! Market Focus Shifts to a December Rate Hike as Warsh Faces a "Major Communications Test"

If the Fed decides to keep rates unchanged this week, Fed Chair Warsh will once again face a familiar challenge: he must convince investors that the Fed is committed to curbing inflation while explaining why officials chose not to raise rates.

1 h ago

WuXi AppTec (02359) Q3 new orders reached RMB26 billion, 1.6 times revenue.

The performance growth mainly came from a surge in orders.

1 h ago

Hui Ching-yu: Hong Kong Ranks First Globally in Fintech; Steering Group Focuses on Virtual Asset Regulation and AI Applications

On October 26, Christopher Hui, Secretary for Financial Services and the Treasury of Hong Kong, chaired the sixth meeting of the Fintech Project Implementation Steering Group, exchanging views with representatives from financial regulators, the fintech sector, and academia on the latest developments in Hong Kong's fintech.

1 h ago

CISI FIN (06058) subsidiary CISI Investment purchased perpetual securities with an aggregate principal amount of US$14.35 million

CISI FIN (06058) announced that its indirectly wholly-owned subsidiary CISI Investment purchased perpetual securities with an aggregate principal amount of US$14.35 million (equivalent to approximately HK$112.6 million) in the open market during the period from April 20, 2026 to October 23, 2026, at a total consideration of approximately US$14.7641 million (equivalent to approximately HK$115.9 million).

1 h ago

No longer merely catching up with inflation! Japan's auto workers' union pushes for even larger wage increases, potentially setting the tone for the 2027 spring wage negotiations.

Japan's largest auto industry union organization is seeking to go beyond merely demanding that wage increases keep pace with inflation in next year's labor-management negotiations.

1 h ago

PBOC: Average daily interbank lending turnover in September was RMB292.54 billion, down 30.5% year-on-year.

In September 2026, net government bond financing was RMB1.53622 trillion, an increase of RMB346.96 billion year-on-year; net corporate bond financing was -RMB39.26 billion, a decrease of RMB52.9 billion year-on-year.

1 h ago

TRIGIANT (01300) pre-wins CHINA TOWER's 2026 centralized procurement project for power cable (copper cable) products

TRIGIANT (01300) announced that on October 22, 2026, China Tower published on its online business platform the announcement of the selection results for China Tower's 2026 centralized procurement project for power cable (copper cable) products (hereinafter referred to as the winning bid announcement). Jiangsu Trigiant Technology Co., Ltd. (hereinafter referred to as Trigiant Technology), a wholly-owned subsidiary of the Group, is a relevant candidate for the winning bid and is the pre-winning bidder for the following specific project:

1 h ago

CITIC SEC (06030) announces its first three quarters results, with net profit attributable to shareholders of RMB31.022 billion, up 32.66% year on year.

CITIC SEC (06030) announced its 2026 third-quarter results. The Group achieved operating revenue of RMB16.898 billion, down 26.59% year on year; net profit attributable to shareholders of the parent company was RMB7.679 billion, down 20.19% year on year; basic earnings per share were RMB0.48.

2 h ago

LEADS BIOLABS-B(09887): Updated Clinical and Translational Data for Vilixin in the Treatment of Extrapulmonary Neuroendocrine Carcinoma, Biliary Tract Cancer, and Colorectal Cancer Published at the 2026 European Society for Medical Oncology (ESMO) Congress

LEADS BIOLABS-B (09887) announced that updated clinical and translational data from four studies of Vilixin (opartusumimab, a PD-L1/4-1BB bispecific antibody) were published at the 2026 European Society for Medical Oncology (ESMO) Congress (2026 ESMO).

2 h ago

Northbound funds | Northbound trading recorded a net sell of RMB2.075 billion. Northbound funds added positions in domestic large models while selling off AI hardware stocks and CNOOC (00883) throughout the day.

On October 26 in the Hong Kong stock market, northbound trading recorded a net sell of HK$2.075 billion. Among this, Stock Connect (Shanghai) recorded a net sell of HK$732 million, and Stock Connect (Shenzhen) recorded a net sell of HK$1.344 billion.

2 h ago

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2005 Injection, SHR-1501 for Injection, and Adebrelimab Injection Receive Drug Clinical Trial Approval Notices

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiaries Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceuticals Co., Ltd. received the Drug Clinical Trial Approval Notices issued and approved by the National Medical Products Administration (hereinafter referred to as the "NMPA") for SHR-2005 Injection, SHR-1501 for Injection, and Adebrelimab Injection, and will commence clinical trials in the near future.

2 h ago

Southbound funds recorded a net sell of RMB 2.075 billion today. On the Stock Connect (Shanghai) side, Tencent Holdings and CNOOC were net sold HKD 427 million and HKD 276 million, respectively; UBTECH led in net buying with HKD 141 million; on the Stock Connect (Shenzhen) side, Alibaba-W and SMIC were net sold HKD 401 million and HKD 310 million, respectively; Zhipu led in net buying with HKD 384 million.

Latest news

2 h ago

ZTE Corporation (00763) announced its third-quarter results, with net profit attributable to shareholders of RMB1.307 billion, up 394.46% year on year.

ZTE Corporation (00763) announced its 2026 third-quarter results. The group recorded operating revenue of RMB38.813 billion, up 33.99% year on year; net profit attributable to shareholders of the listed company was RMB1.307 billion, up 394.46% year on year; basic earnings per share were RMB0.27.

2 h ago

BEIJING ENT (00392): Yanjing Huiqian's net profit attributable to shareholders for the first three quarters was RMB116 million, up 17.71% year on year.

Beijing Enterprises Holdings (00392) announced that its subsidiary Fujian Yanjing Huiqian Brewery Co., Ltd. (Yanjing Huiqian) recorded operating revenue of RMB587 million for the first three quarters of 2026, up 2.03% year on year; profit attributable to shareholders of Yanjing Huiqian was RMB116 million, up 17.71% year on year.

2 h ago

HELENS (09869) will pay a special dividend of HK5.539 cents per share on November 24.

HELENS (09869) announced that it will pay a special dividend of HK5.539 cents per share on November 24, 2026.

2 h ago

Shanghai: Support enterprises in planning and building gateway stations globally, and deploy and build satellite-ground interconnection centers in due course.

Shanghai has issued the "Shanghai Satellite Internet Industry Innovation and Development Action Plan." It mentions support for enterprises to plan and build gateway stations globally, deploy and construct satellite-terrestrial interconnection centers in due course, build a ground-segment communications support network, and optimize the coverage and communication quality of satellite networks. It supports satellite internet enterprises and telecom operators in jointly building and sharing ground-segment communications infrastructure, achieving seamless connection of communication links across systems, networks, and regions.

Latest news

2 h ago

WuXi AppTec (02359): Profit attributable to shareholders for the first three quarters was RMB19.161 billion, up 62.36% year on year.

WuXi AppTec (02359) announced that for the first three quarters of 2026, it achieved revenue of RMB45.54 billion (the same below), up 38.6% year on year, with revenue from continuing operations up 46.3% year on year; profit attributable to owners of the parent for the period was RMB19.161 billion, up 62.36% year on year; basic earnings per share were RMB6.58.

3 h ago

HKEX: Price limit threshold for all securities orders tightened from nine times to five times, effective November 2

On October 26, Hong Kong Exchanges and Clearing Limited issued an announcement stating that the Securities and Futures Commission of Hong Kong has approved the relevant exchange rule amendments to tighten the price limit threshold for orders in all securities (excluding structured products) from the current nine times to five times.

3 h ago

InnoCare Pharma (09969) reported net profit attributable to shareholders of approximately RMB656 million for the first three quarters, turning profitable year-on-year.

InnoCare Pharma (09969) announced its results for the first three quarters of 2026. Total operating revenue was RMB2.099 billion, up 88.21% year on year, of which pharmaceutical sales revenue was RMB1.449 billion, up 41.47% year on year. The growth in operating revenue was mainly due to the continued volume expansion of the core product orelabrutinib, the incremental sales contribution from tafasitamab and zurletrectinib, and the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc. Net profit attributable to shareholders of the listed company was approximately RMB656 million, turning profitable year on year.

3 h ago

GAPACK (00468) attributable profit to shareholders for the first three quarters was RMB14.223 million, down 81.52% year-on-year.

GAPACK (00468) announced its results for the nine months ended September 30, 2026. The Group recorded revenue of RMB1.299 billion (same unit below), down 7.86% year-on-year; profit attributable to owners of the Company was RMB14.223 million, down 81.52% year-on-year.

3 h ago

POLY PROPERTY (00119): Shanghai Poly Property recorded a net loss attributable to shareholders of RMB816 million in the first nine months, turning from profit to loss year-on-year.

Poly Property Group (00119) announced the results of Shanghai Poly Property for the first nine months of 2026, with operating revenue of RMB19.323 billion, a year-on-year decrease of 15.09%; the net loss attributable to owners of the parent company was RMB816 million, turning from profit to loss year-on-year.

3 h ago

GD LAND (00124) reported attributable profit of HK$258 million for the first three quarters, turning from a loss to a profit year-on-year.

GD LAND (00124) announced that for the nine months ended September 30, 2026, the Group's consolidated revenue was approximately HK$5.367 billion (nine months ended September 30, 2025: HK$6.728 billion), a decrease of approximately 20.2% year-on-year. The decrease in revenue was mainly due to a reduction in the total gross floor area (GFA) sold of properties held for sale. During the review period, the Group recorded a profit attributable to owners of the Company of approximately HK$258 million (nine months ended September 30, 2025: loss of HK$16 million).

3 h ago

GLORY SUN LAND (00299): The Listing Committee has decided to cancel the listing status of the Company's shares.

Glory Sun Land (00299) announced that on October 23, 2026, the Company received a letter from the Stock Exchange (the Letter), stating that the Listing Committee of the Stock Exchange (the Listing Committee) has decided to cancel the listing status of the shares under Rule 6.01A(1) of the Listing Rules (the Decision), because the Listing Committee considers that the Company did not fulfill all the resumption guidance by September 30, 2026 and did not resume trading of the shares on the Stock Exchange.

3 h ago

BINHAI INV (02886): Gas sales volume for the first three quarters increased by approximately 4% year-on-year; value-added services broaden growth space.

After the market close on October 26, Binhai Investment (02886) released its business update for the first three quarters ended September 30, 2026. Based on the unaudited operating data disclosed in the announcement, the company's traditional piped gas main business maintained steady growth, with the user base continuing to expand, while its two new business segmentsvalue-added services and integrated energywere implemented in an orderly manner, as the group advanced the optimization of its business structure in line with its established strategy.

3 h ago

CIMC ENRIC (03899) reported a net profit attributable to shareholders of RMB817 million for the first three quarters, up 6.5% year on year.

CIMC ENRIC (03899) announced that for the first three quarters of 2026, the Group recorded revenue of RMB20.52 billion, up 6.0% year on year; net profit of RMB836 million, up 5.3% year on year; and profit attributable to shareholders of RMB817 million, up 6.5% year on year. In the third quarter, the Group recorded revenue of RMB7.635 billion, up 13.4% year on year; net profit of RMB310 million, up 45.5% year on year; and profit attributable to shareholders of RMB300 million, up 47.1% year on year.

3 h ago

UK Plans to Increase Short-Dated Debt Issuance, Potentially Lowering Gilt Yields; Investors Also Closely Watching Whether the Autumn Budget Can Maintain Fiscal Discipline

The UK is about to increase its use of short-dated debt. This shift could push down gilt yields and ease the country's increasingly strained public finances. At the same time, the market reaction that the autumn budget may trigger still warrants vigilance for its impact on the gilt market.

3 h ago

LI NING (02331): E-commerce virtual store business achieved high single-digit growth in the third quarter

LI NING (02331) announced that for the third quarter ended September 30, 2026, retail sell-through for Li Ning sales points (excluding Li Ning YOUNG) across the entire platform recorded a low-single-digit decline year-on-year. By channel, offline channels (including retail and wholesale) recorded a mid-single-digit decline, of which the retail (direct operation) channel was flat, while the wholesale (franchised distributors) channel recorded a mid-single-digit decline; the e-commerce virtual store business achieved high-single-digit growth.

3 h ago

YUE YUEN IND (00551) Issues Profit Warning: Expects Profit Attributable to Owners of the Company for the First Three Quarters to Decrease by Approximately 50% to 55% Year-on-Year

Yue Yuen Industrial (00551) announced that the Group expects profit attributable to owners of the Company for the first three quarters of 2026 to decrease by approximately 50% to 55% year-on-year, primarily due to multiple challenges in the operating environment of the Group's manufacturing business, with weak demand leading to a decline in sales scale, compounded by rising costs and pressure on production efficiency, which have had a negative impact on the gross profit margin of the Group's manufacturing business during the period.

3 h ago

LEPU BIO (02157): 2026 ESMO Congress Data Readout: CMG901 (AZD0901) Clinical Results Reported as an LBA Preferred Paper at the Presidential Symposium

LEPU BIO (02157) announced the Phase III clinical trial results of CMG901 (AZD0901) for second-line and later-line (2L+) CLDN18.2-positive advanced/metastatic gastroesophageal cancer (GEC); the latest clinical results of MRG007 (ARR-217) (a potential best-in-class CDH17-targeting exatecan antibody-drug conjugate (ADC) for the treatment of colorectal cancer (CRC)); and the Phase II trial results of the PD-1 inhibitor pucotenlimab (HX008) combined with MRG003 (vebrekotug monatab) as induction therapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

3 h ago

HUTCHMED (00013) Announces SANOVO Phase III Study Data of ORPATHYS Combined with TAGRISSO for First-Line Treatment of EGFR-Mutated Lung Cancer at the 2026 European Society for Medical Oncology (ESMO) Congress

HUTCHMED (00013) announced positive results from the SANOVO China Phase III study. In treatment-nave patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor ("EGFR") mutations and MET overexpression, the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of progression-free survival ("PFS") compared with TAGRISSO monotherapy. The combination therapy also showed highly encouraging clinical benefit in overall survival ("OS"), one of the study's secondary endpoints.

3 h ago

SSY GROUP (02005) reported profit attributable to shareholders of approximately HK$460 million for the first three quarters, up 15.5% year-on-year.

SSY GROUP (02005) announced that the Group's unaudited revenue for the nine months ended September 30, 2026 was approximately HK$3.52 billion (same period in 2025: approximately HK$3.102 billion), up 13.5% year-on-year, mainly due to the resumption of growth in the Group's intravenous infusion and active pharmaceutical ingredients businesses.

3 h ago

Ministry of Commerce: Solicits Public Comments on the Special Provisions on the Protection of China's Commercial Secrets, Clarifying Investigation and Countermeasure Measures Against Foreign Entities

The Ministry of Commerce has drafted the Special Provisions on the Protection of China's Commercial Secrets (Draft for Comment) and is now soliciting public comments.

3 h ago

iFlytek Spark Medical LLM V3.7 upgraded; AI Patient Management 3.0 released and industry standard co-development launched

At the concurrently held AI Patient Management Innovation Forum, iFlytek Healthcare released the AI Patient Management Platform 3.0 and, together with domestic top-tier hospitals and authoritative research institutions, launched the AI Patient Management Expert Consensus Special Program, leading the standardized and intelligent upgrade of the AI patient management industry across three dimensions: technological breakthroughs, product iteration, and co-development of standards.

3 h ago